Featured Videos

SAN FRANCISCO, CA USA (UroToday.com) - While the role of sequential sorafenib (SO) and sunitinib (SU) has been examined retrospectively, no prospective trials have been performed to date.

Dr. Maurice-Stephan Michel presented results from the first prospective, randomized controlled trial of sequential SO/SU versus SU/SO for metastatic RCC. Patients with metastatic RCC with good PS and no prior exposure to cytokines or systemic therapy were randomized to SO/SU (n=182) or SU/SO (n=183). gucancerssympalt thumbThe primary endpoint examined was total PFS from randomization to event during second-line therapy. Baseline characteristics were well balanced between groups. There was no significant difference in total PFS (HR 1.01, p=0.54) or OS between treatment arms (HR 0.997, p=0.49). Median OS was 31.5 vs 30.2 months for SO/SU and SU/SO, respectively. Fewer patients crossed over to receive SO in the SU/SO arm.

The most frequent adverse events for first-line treatment included alopecia (29% SO vs 4% SU), diarrhea (43% SO vs 29% SU), fatigue (21% SO vs 34% SU), hypertension (24% SO vs 24% SU), nausea (18% SO vs 24% SU), and rash (22% SO vs 3% SU). Overall, adverse events were lower during second-line therapy.

In conclusion, both drugs provided overall benefit regardless of sequence, with no significant difference in total PFS and OS between the two sequential treatments. More patients reached second-line therapy in the SO/SU arm.

Highlights of a presentation by Maurice-Stephan Michel, MD, PhD at the 2014 Genitourinary Cancers Symposium - January 30 - February 1, 2014 - San Francisco Marriott Marquis - San Francisco, California USA

Rhode Island Hospital, Providence, RI USA

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com

View Full 2014 GU Cancers Symposium Coverage




Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.